ATT Ltd, a biopharmaceutical company, has lodged a prospectus with ASIC intending to raise $100 million from investors. The aim of the capital raising is to allow the company to develop its range of research and development products. In the company's prospectus, ATT Ltd has provided for forecast earnings/losses for the next three years as follows: 15 million loss during the first year, $25 million loss during the second year and $10 million profit in the third year. The earnings forecast is based on the company expecting to complete development of a medicine for Covid-19 which is currently under clinical trial. However, preliminary evidence from the trial reveals the vaccine has not shown conclusive results. The results from the clinical trail have not been disclosed in the prospectus. 1) Advise whether ATT Ltd is in breach of any of its Ch 6D disclosure obligations. 2) What possible remedies could investors have if they have relied on ATT's prospectus to purchase securities in the company?

Irac answer, detail as possible